Dr. Brian Persing, a medical oncologist and hematologist in Mobile, Alabama and member of the Association of Clinical Oncology (ASCO), the world’s leading professional organization representing nearly 45,000 oncology professionals, will testify before the House Appropriations Subcommittee on Labor Health and Human Services and Education today in support of increased federal funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control. He will also advocate for robust funding of the Advanced Research Projects Agency for Health (ARPA-H).
March 23, 2023
ASCO Member Testifies Before Congress Urging Significant Increase in Federal Cancer Research Funding
March 21, 2023
Zolbetuximab in combination with chemotherapy extends survival in patients with 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. These results will be presented during the March 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
March 15, 2023
ALEXANDRIA, Va. – In a study of more than 1,100 people with COVID-19 undergoing treatment for cancer, researchers found lower COVID-19 vaccination rates among patients with comorbidities, metastatic solid tumors or non-B-cell hematologic malignancies, and those living in areas with lower education attainment and higher levels of unemployment. The study, funded by Conquer Cancer®, the ASCO Foundation, was published today in Cancer.
March 9, 2023
Today President Biden released his proposed Fiscal Year (FY) 2024 federal budget with an emphasis on increased funding for medical research and expanded access to health insurance.
February 18, 2023
Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.
February 18, 2023
Eight notable studies exploring new approaches in the treatment and management of genitourinary cancers will be presented at the 2023 ASCO Genitourinary Cancers Symposium, taking place February 16-18, 2023, at the Moscone West Building in San Francisco, California.
February 16, 2023
Polymerase Inhibitor Significantly Improves Progression-Free Survival for Metastatic Prostate Cancer
The TALAPRO-2 phase III clinical trial found that a polymerase inhibitor combined with an androgen receptor inhibitor had significantly better progression-free survival (PFS) versus the current standard of care for people with metastatic, castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair pathway status. Homologous recombination repair involves a pathway that can help fix DNA double-strand breaks and cross-links between DNA strands.
February 14, 2023
In patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy. These results will be presented during the February 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
February 13, 2023
Study participants with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of the cancer progressing and a 53% lower risk of recurrence compared to those who had the lowest amounts of plants in their diets. The diet assessments were based on questionnaires of food consumption given to people enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study.
February 8, 2023
“ASCO applauds President Biden’s focus on ‘ending cancer as we know it’ during the State of the Union address. We continue to urge the president to keep cancer care and research as top national priorities and are pleased with his plans to advance efforts to strengthen the Cancer Moonshot, improve cancer clinical trials, and foster breakthroughs through the Advanced Research Projects Agency for Health (ARPA-H).”
February 7, 2023
In anticipation of President Biden’s State of the Union Address, the Association for Clinical Oncology (ASCO) is urging the president to keep cancer care and research as top national priorities.
February 6, 2023
Two prostate cancer studies – one examining the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide and one on plant-based diets and disease progression – will be highlighted in the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 800 abstracts that will be presented at the Symposium.
February 2, 2023
Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.
January 23, 2023
A non-invasive blood test may help to determine the most effective treatment for patients with advanced gastrointestinal stromal tumors (GIST) that has progressed or is intolerant to first-line imatinib. These results will be presented during the January 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
January 21, 2023
SAN FRANCISCO – Eleven noteworthy studies exploring new approaches in the treatment and management of gastrointestinal cancers will be presented at the 2023 ASCO Gastrointestinal Cancers Symposium, taking place January 19-21, 2023, at the Moscone West Building in San Francisco, California.
Pages |